NCT06044857 2026-04-14
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase 1 Recruiting
Clinical Trials
20 trialsNCT06022822 2026-04-13
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03361735 2026-04-09
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05050084 2026-04-08
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06798558 2026-03-23
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Hackensack Meridian Health
Phase 2 Recruiting
NCT03274687 2026-03-16
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT06654336 2026-03-13
RATIONAL
Ontario Clinical Oncology Group (OCOG)
Phase 2 Recruiting
NCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT04943536 2026-02-27
BiolenRT
Alessa Therapeutics Inc.
Phase 1 Active not recruiting
NCT06257693 2026-02-27
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Alessa Therapeutics Inc.
Phase 1 Recruiting
NCT04704505 2026-02-06
BAT-RAD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT04175431 2025-12-18
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
University of Washington
Phase 2 Recruiting
NCT05998278 2025-12-18
Personalized Optimization of Systematic Prostate Biopsy
Fujian Medical University Union Hospital
Phase NA Recruiting
NCT04543903 2025-12-02
Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer
Alpha Tau Medical LTD.
Phase NA Completed
NCT07251829 2025-11-26
Neoadjuvant Embolization and Cytoreduction in Prostate Cancer
British Columbia Cancer Agency
Phase 2 Not yet recruiting
NCT03860961 2025-11-03
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
NRG Oncology
Phase NA Completed
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT07210502 2025-10-07
LDR BURST
Royal Surrey County Hospital NHS Foundation Trust
Phase NA Not yet recruiting
NCT04743934 2025-05-04
RAD 2003
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT05665738 2025-04-29
Two-fraction HDR Monotherapy for Localized Prostate Cancer
University of California, San Francisco
Phase NA Recruiting